Latest news
Darlifarnib Plus Cabozantinib Shows Durable Activity in Advanced RCC - Targeted OncologyTargeted Oncology · Mon, 27 Jul 2026 15:10:16 GMTKURA: Darlifarnib plus cabozantinib showed up to 50% response rates and durable benefit in advanced ccRCC - TradingViewTradingView · Mon, 27 Jul 2026 11:35:16 GMTKura Oncology Reports Durable Clinical Activity of - GlobeNewswireGlobeNewswire · Mon, 27 Jul 2026 10:32:00 GMT